文献速递外周动脉疾病

戒烟辅助措施在外周动脉疾病择期血运重建前具成本效益

Smoking Cessation Adjuncts Are Cost Effective Prior to Elective Revascularization.
PubMed 文献 · Ann Vasc Surg · 2025-08-14

研究用Markov模型评估65岁症状性PAD患者行开放或腔内血运重建前五种戒烟策略的成本效益,以10万美元/QALY为支付阈值。结果显示伐尼克兰与尼古丁替代疗法最具成本效益,伐尼克兰在概率模拟中80.3%更优。

要点

  • 伐尼克兰QALY最高(7.11),标准护理最低(6.43)。
  • 伐尼克兰与NRT是最具成本效益的戒烟策略。
  • 概率模拟中伐尼克兰在10万美元/QALY阈值下80.3%更优。

核心结论

  • PAD择期血运重建前使用戒烟辅助措施具成本效益,伐尼克兰与NRT为最具成本效益策略。

研究设计与样本

  • 采用Markov模型评估65岁症状性PAD患者行开放或腔内血运重建前五种戒烟策略的成本效益。
  • 戒烟治疗成本来自本地数据,疗效与术后结局频率及费用来自已发表文献。
  • 成本以美元、效果以QALY衡量,支付阈值为10万美元/QALY,并行概率模拟1000次及单因素敏感性分析。

主要发现

  • 基础案例中标准护理成本最低(326,280美元)且效果最低(6.43 QALY)。
  • 伐尼克兰成本最高(333,335美元)但效果最高(7.11 QALY)。
  • 伐尼克兰与NRT为最具成本效益的疗法。
  • 概率模拟中伐尼克兰在10万美元/QALY阈值下80.3%更优。
  • 假设吸烟状态无死亡率差异时,单因素敏感性分析中伐尼克兰优于所有其他疗法。

关键数值与推荐

  • 支付阈值设定为10万美元/QALY。
  • 基础案例标准护理成本326,280美元、效果6.43 QALY;伐尼克兰成本333,335美元、效果7.11 QALY。
  • 概率模拟1000次中伐尼克兰在10万美元/QALY下80.3%更优。

临床怎么用

  • PAD患者择期血运重建前可优先考虑伐尼克兰或NRT作为戒烟辅助。
  • 结果支持对PAD血运重建患者戒烟治疗给予补充覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preoperative smoking cessation can reduce adverse postoperative outcomes. Investment in smoking cessation therapies has therefore proven cost effective prior to elective interventions across numerous disciplines. Despite high rates of smoking among patients with peripheral artery disease (PAD), the cost effectiveness of smoking cessation before elective revascularization is unclear. METHODS: Using a Markov model, we evaluated the cost effectiveness of preoperative smoking cessation therapies (standard care, counseling, nicotine replacement therapy [NRT], varenicline, bupropion) for 65-year-old patients undergoing open or endovascular revascularization for symptomatic PAD. Local data quantified smoking cessation therapy costs. Established literature informed therapy effectiveness, postoperative outcomes (stroke, myocardial infarction, major amputation, patency, death) frequencies, and postoperative costs. Lifetime costs were quantified in US dollars and effectiveness in quality-adjusted life-years (QALYs), with a willingness-to-pay threshold of $100,000/QALY gained. Sensitivity analyses tested model robustness. RESULTS: In the base-case scenario, standard care was least expensive ($326,280) and varenicline was costliest ($333,335). However, varenicline was the most effective (7.11 QALYs), while standard care was least effective (6.43 QALYs). NRT and varenicline were the most cost-effective therapies. In the probabilistic simulation (randomly varying model parameters over 1,000 iterations), varenicline was favored in 80.3% at $100,000/QALY gained. Assuming no mortality differences by smoking status, in one-way sensitivity analyses varenicline dominated all other therapies. CONCLUSION: Smoking cessation adjuncts are cost effective prior to PAD interventions. Varenicline and NRT were the most cost-effective smoking cessation strategies. Our results highlight the value of supplemented coverage for smoking cessation therapies among patients with PAD undergoing revascularization.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Nassereldine H, Reitz KM, Lowenkamp M, et al. Smoking Cessation Adjuncts Are Cost Effective Prior to Elective Revascularization. Ann Vasc Surg. 2025. PMID: 40818813. doi:10.1016/j.avsg.2025.08.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。